In a report released yesterday, Cory Kasimov from J.P. Morgan maintained a Buy rating on Global Blood Therapeutics (GBT), with a price target of $75. The company’s shares closed yesterday at $53.08.
According to TipRanks.com, Kasimov is a 3-star analyst with an average return of 1.3% and a 42.5% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals Inc, Allogene Therapeutics Inc, and Jounce Therapeutics Inc.
Global Blood Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $89.11, representing a 67.9% upside. In a report issued on February 22, Guggenheim also initiated coverage with a Buy rating on the stock with a $75 price target.
See today’s analyst top recommended stocks >>
Based on Global Blood Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $43.07 million. In comparison, last year the company had a GAAP net loss of $41.25 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases.
